The Novo Nordisk Foundation (NNF), Wellcome, and the Gates Foundation (GF) are jointly launching a new $5,000,000 initiative, Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), to drive innovation in early drug discovery for Gram-negative pathogens.